1/17/2024 0 Comments
Far too frequently do we see early-stage companies select a preclinical pathway for the wrong drug candidate targeting the wrong indication, inevitably leading to increased costs and delayed program advances, much of which can be avoided with input from an experienced Chief Medical Officer (CMO) executive. To that end I wanted to reach out to highlight our creation of the BJC Capital Advisors’ CMO executive network and underscore the benefit, especially for companies in preclinical development, of accessing an experienced CMO talent to align preclinical programs with your anticipated clinical development strategy.
We have assembled our CMO network with experienced industry executives whose background typically combines exposures to both large pharmaceutical and smaller biotechnology companies. This diverse range of experiences provides our CMOs with an understanding of big company culture and expectations as well as an appreciation of the constraints small companies often face. We find this blend of insights maximizes the value our CMOs bring to client engagements. Executive talent can be accessed on either a fractional or interim basis, for as little as a few hours a month, with engagements structured to best accommodate company budgets. Accessing a CMO in this manner provides a functional solution for companies where the significant expense of a full-time hire is not justified.
I imagine many of these perspectives may resonate with you. If so, we encourage you to please reach out to learn more about our CMO executive network and how our senior-level talent can benefit your development initiatives.
About the Author
Ben Conway is a long-tenured investment banker with a primary focus on the biopharmaceutical sector. In addition to investment banking, his experience includes positions in large pharma as well as with smaller emerging biotech platforms.